Insights Into Lung Cancer

Perspectives on drivers in treatment decisions in the management of lung cancer

Southwest – February 28, 2022

Faculty Chair

Luis Raez, MD

Memorial Cancer Institute

Central – March 29, 2022

Faculty Chair

Narjust Duma, MD

Dana-Farber Brigham Cancer Center

Southeast – May 17, 2022

Faculty Chair

Stephen Liu, MD

Georgetown Lombardi Comprehensive Cancer Center

Northeast – August, 2022

Faculty Chair

TBC

TBC

Midwest – September, 2022

Faculty Chair

TBC

TBC

Northwest – November, 2022

Faculty Chair

TBC

TBC

More Information

  • Virtual series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Virtual series
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Virtual series
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee,  Virginia, West Virginia

More Information

  • Philadelphia, PA
  • Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Chicago, IL
  • Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio

More Information

  • Portland, OR
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

Example Agenda

Export meeting topics

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of lung cancer
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained on the management of RET rearrangement-positive non-small cell lung cancer (NSCLC) and current treatment options for this malignancy used in community practices

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.